Humulina Nph Kwikpen (Insulin Human)

Humulina NPH KwikPen is indicated for the management of blood glucose in adults with diabetes.

• For adults with type 1 diabetes mellitus requiring basal insulin support.
• For adults with type 2 diabetes mellitus when oral agents are insufficient.
• Provides basal insulin coverage to help maintain fasting and between‑meal glucose levels.
• Can be used together with rapid‑acting insulin analogues for a basal‑bolus regimen.
• Suitable for patients who need a longer‑acting insulin to achieve stable glycemic control.
• Dose may be individualized to meet personal treatment goals and carbohydrate intake.

• Insulin human NPH is a recombinant form of human insulin that binds to insulin receptors on the surface of muscle, adipose and hepatic cells. Receptor activation triggers intracellular signaling cascades, primarily the phosphoinositide 3‑kinase (PI3K) pathway, which promotes translocation of glucose transporter type 4 (GLUT4) to the cell membrane, enhancing glucose uptake. In the liver, insulin suppresses gluconeogenesis and glycogenolysis, thereby lowering circulating glucose levels.

Adverse reactions to Humulina NPH KwikPen may vary in frequency and severity, ranging from mild, self‑limiting events to rare, potentially life‑threatening conditions.

Common

• Mild hypoglycemia, characterized by transient symptoms such as shakiness, sweating, or dizziness, which usually resolves with carbohydrate intake.
• Localized redness, swelling, itching, or bruising at the injection site, often disappearing within a few days without lasting effects.
• Development of small lumps of fatty tissue (lipohypertrophy) at repeated injection sites, which may alter insulin absorption and require site rotation.

Serious

• Severe hypoglycemia that can cause confusion, seizures, loss of consciousness, or require assistance from another person to recover.
• Allergic reactions may appear as rash, hives, itching, facial or throat swelling, and in rare cases, anaphylactic shock.
• Marked fluid retention or edema leading to rapid weight gain, shortness of breath, and possible strain on the cardiovascular system.

When using Humulina NPH KwikPen, certain precautions should be observed to ensure safe and effective therapy.

• Verify the correct dose and inspect the pen for any damage before each injection.
• Rotate injection sites within the abdomen, thigh, or upper arm to reduce lipohypertrophy risk.
• Monitor blood glucose regularly, especially when initiating therapy or adjusting the dose.
• Adjust the dose in situations such as illness, changes in diet, or increased physical activity.
• Use caution in patients with renal or hepatic impairment, as insulin clearance may be altered.
• Pregnant or breastfeeding women should consult a healthcare professional before use.
• Store the pen according to manufacturer instructions, protecting it from extreme temperatures.

Humulina NPH KwikPen may interact with other medicines, potentially altering glucose control, enhancing hypoglycemia risk, or requiring adjustments to the insulin dose.

Avoid

• Using additional insulin types (e.g., rapid‑acting) without proper dose adjustment can cause severe hypoglycemia.
• High‑dose non‑selective beta‑blockers may mask hypoglycemia symptoms, making low blood sugar harder to recognize.
• MAO‑A inhibitors can enhance insulin’s glucose‑lowering effect, increasing hypoglycemia risk.

Use with caution

• Sulfonylureas or meglitinides combined with insulin raise hypoglycemia risk; monitor glucose closely and adjust doses as needed.
• Systemic corticosteroids increase hepatic glucose output, often requiring a higher insulin dose to achieve target levels.
• Thyroid hormone therapy or excess thyroid activity can alter insulin sensitivity, possibly needing dose changes.